MEDICATION USE AND ASSOCIATED ANNUAL COSTS IN PATIENTS AT RISK OFATHEROTHROMBOSIS: RESULTS FOR GERMANY, SPAIN AND THE UK FROM THE REDUCTION OFATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY

Mahoney EM1, Wang K1, Bruggenjurgens B2, Bakhai A1

1New England Research Institutes, Watertown, MA, USA, 2Charite University Medical Center, Berlin, Germany, 3Barnet & Chase Farm NHS Trust, Barnet, UK

OBJECTIVES: Atherothrombosis is the leading cause of death worldwide which creates a huge economic burden. The REACH Registry is an international prospective registry with 67,888 patients from 44 countries, at risk of atherothrombotic events due to coronary artery (CAD), cerebrovascular (CVD) and/or peripheral arterial disease (PAD), or the presence of ≥3 atherothrombotic risk factors. METHODS: We examined medication (MED) use and estimated annual MED costs ($ in 5594, 2516, and 618 patients from Germany (GE), Spain (SP) and the UK, respectively, using baseline data from REACH. Classes of drugs examined included antiplatelet agents, oral anticoagulants, NSAIDS, lipid lowering agents, antihypertension agents, nitrates or other anti-angina agents, and peripheral arterial claudication medications. Country-specific unit costs were obtained for the 3–4 most commonly prescribed drugs in each MED category, and a weighted average of MED-specific costs, by market share, was applied to annualized utilization rates. RESULTS: Within each country, average # MEds increased with # diseased vascular sites (GE:3.6/4.3/5.0;SP:3.4/4.3/4.8;UK:3.6/4.2/4.7, for 0/1/2–3 vascular sites, respectively). Patients with CAD only reported greater # MEds (GE:4.7;SP:4.5;UK:4.4) than patients with CVD only (GE:3.7;SP:3.0;UK:3.3) or PAD only (GE:3.5;SP:2.5;UK:3.1). Greater than two thirds reported taking at least 1 lipid lowering agent (GE:74%;SP:68%;UK:85%), and >85% reported taking at least 1 antihypertensive agent (GE:94%;SP:96%;UK:88%). Average costs were higher for GE compared to SP and UK due to higher unit costs for nearly all MEds. Lipid lowering and antihypertensive agents accounted for >50% of MED costs (GE:70%;SP:54%;UK:76%). Costs tended to increase with # diseased vascular sites (GE:$770/$993/$1164;SP:$492/$586/$710;UK:$546/$553/$668, for 0/1/2–3 vascular sites, respectively). CONCLUSION: In this population of patients with either stable vascular disease or multiple atherothrombotic risk factors, use of multiple medications was common. Medication use and associated costs tend to increase with the number of diseased vascular sites, and contribute to the economic burden of atherothrombosis.

EFFICACY AND SOCIOECONOMIC RELEVANCE OF HAWTHORN EXTRACT (CRATEAGUS WS® 1442) IN THE TREATMENT OF NYHA II CHF PATIENTS—RESULTS FROM A PROSPECTIVE THREE-YEAR PHARMACOECONOMIC STUDY

Rychlik R1, Ermen C1, Daniel D1, Klapper HG2, Habs M3

1Institute of Empirical Health Economics, Burscheid, NRW, Germany, 2Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Baden-Württemberg, Germany

OBJECTIVES: To evaluate the pharmacoeconomics of hawthorn extract (crataegus), compared to any other therapy of congestive heart failure (CHF), NYHA II, a prospective, 3-year, observational cohort study was conducted from 1999 to 2002. A cost-utility-analysis was performed to compare the direct costs of the treatment alternatives proportional to health related quality-of-life (costs per quality-adjusted life year), METHODS: The open observational study with matched-pairs evaluation included general practitioners and internists. The crataegus cohort (CC) comprised patients who received WS® 1442 for CHF (mono or add-on). In the Standard cohort (SC), patients who received any other treatment but crataegus were observed. Efficacy and tolerability of the treatment alternatives were evaluated. Calculation of the direct costs of the treatment comprised costs for diagnostic and therapeutic measures, drugs and hospitalisations, cure and rehabilitation measures. For measuring the patients’ quality-of-life and calculating the gained quality-adjusted life years (QALY), the EuroQoL-5D was applied. RESULTS: Data of 153 pairs (306 patients) were available for the statistical analysis. The pairs were established based on age, gender and concomitant cardiac diseases. Both efficacy and tolerability of the crataegus therapy were evaluated as significant superior to standard therapy. Mean direct costs per year amounted to €807.15 in cohort C and €798.09 in cohort S. Gained quality-adjusted life years were 0.080 and 0.078 in the C- and the S-cohort, respectively. CONCLUSIONS: Direct costs and gained QALY were similar in both cohorts. Both mono and add-on applications of crataegus extract in the treatment of congestive heart failure, NYHA II, represent a cost-effective alternative compared to standard medication. Crataegus treatment was associated with a substitution of standard medication like ACE-inhibitors and diuretics. Concerning the documented very good tolerability of crataegus and the need of long-term treatment of the considered indication, crataegus therapy provides an additional benefit for the affected patients.